BPH Global Ltd

Seaweed-Sourced Energy R&D Program Further Refined - Focus on Biohydrogen and Essential Mineral Extraction

The Board ofBPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company has further reviewed and refined its R&D program, and in particular, its Seaweed-sourced energy R&D program.


Highlights

  • Key features of the R&D program:
    • Fermentation: Harvested seaweed to be processed by fermentation (Anaerobic Digestion).
    • Biohydrogen Extraction: Production of biohydrogen/biogases as a natural by-product of fermentation.
    • Essential Mineral and Nutraceutical extraction: Fermentation to unlock essential minerals and nutraceuticals.
    • Artificial Intelligence technology (AI): AI to be developed and deployed to enhance essential mineral and nutraceutical identification and extraction.
    • Commercialisation: R&D focussed on potential commercialisation opportunities.
The Company had previously announced that it was expanding its R&D program to include R&D into the extraction of individual macro minerals and micro minerals from seaweed and sea plant biomass, to enable the sale of those macro and micro minerals to the commodities markets, and to industry specific markets such as the battery industry, and thereby create additional revenue streams for the Company. In that same announcement, the Company also stated that it would investigate both pyrolytic and non- pyrolytic/low heat extractive strategies to determine the highest yield of targeted essential minerals and chemical compounds out of selected seaweed species.

Since that announcement, the Company has continued to review and refine its R&D program. In doing so, the Company has considered factors such as environmental impacts and benefits; development costs; prospects of achieving proof of concept; and the likelihood of successful commercialisation. The Company has decided to focus its R&D on the non-pyrolytic/low heat process of fermentation (Anaerobic Digestion) as its preferred extractive strategy. The process of fermentation produces an intermediate liquid product from which essential minerals (and nutraceuticals) can be extracted. In addition, a by-product of that fermentation process is the production of biogases, principally biohydrogen and biomethane.

Consequently, the Company has decided it will now focus its energy related R&D program on these two related activities:

  • Production and extraction of biohydrogen/biogases; and
  • Extraction of essential minerals.

1. Biohydrogen/biogas production

Production of biohydrogen/biogas a natural by-product of fermentation: The process of fermentation (Anaerobic Digestion) transforms seaweed biomass to an intermediate liquid product from which essential minerals (and nutraceuticals) can be extracted. A by-product of that fermentation process is the production of biogases, principally biohydrogen and biomethane. A major source of renewable energy, biogas is created by the breakdown of organic matter in the absence of oxygen. It is produced by the anaerobic digestion of various organic materials including municipal waste, farm waste, food waste and energy crops. The Company will undertake a R&D program on the production of biogases from seaweed as a by- product of the extraction of essential minerals and nutraceuticals from seaweed. Biogas can be stored in tanks and transported. Biodigesters reduce methane emissions, making biogas a smart and valuable climate and clean air energy solution.

Illustration of the Company’s R&D Program regarding the extraction of essential minerals from seaweed using the fermentation extractive method and the production of biogases (biohydrogen and biomethane) as a by-product

  • Proposed R&D program and pathway to commercialisation: The Company’s R&D program regarding the production of biogases from seaweed will focus on the:
    • production of pure biohydrogen and biomethane through a process of upgrading the biohydrogen and biomethane yields obtained from the fermentation process;
    • use of pure biohydrogen and pure biomethane as the fuel source for a coastal biogas pilot plant; and
    • sale of biohydrogen and biomethane to energy companies.

  • Biogas Genset System: Biogas can be used as a fuel to generate electricity using a small scale genset. Biogas is converted to mechanical energy through an internal combustion engine. The mechanical energy rotates an electric generator which produces the electricity.

Click here for the full ASX Release

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BP8:AU
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BPH Global

BPH Global

Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment being sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product includes Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.
Radiopharm Theranostics

Radiopharm Theranostics Receives FDA IND Approval for Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has received clearance for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), for F18-Pivalate (RAD 101).

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×